Breaking News, Financial News

Johnson & Johnson 1Q Results

Pharmaceutical sales up 10% in the quarter driven by DARZALEX, STELARA, INVEGA SUSTENNA, and IMBRUVICA.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Johnson & Johnson 1Q Revenues: $22.3 billion (+8%) 1Q Earnings: $6.2 billion (+7%) Comments: Pharmaceutical sales were $12.2 billion in the quarter, up 10%. Sales growth in the quarter was driven by DARZALEX ($3.6 billion, +19%) for the treatment of multiple myeloma, STELARA ($2.1 billion, +18%) for the treatment of immune-mediated inflammatory diseases, ERLEADA ($261 million, +83%), a next-gen androgen receptor inhibitor for prostate cancer, TREMFYA ($418 million, +41%) for moderate to s...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters